"For those who are unable to take HRT for varying reasons, options have historically been limited, and we have heard clearly from patients how difficult that has been. The evidence shows fezolinetant can meaningfully reduce symptoms, and was found to be cost effective, offering value for the taxpayer. This decision will give much-needed relief to those for whom HRT is unsuitable."
"Menopausal hot flushes and night sweats can have a major impact on the quality of life of women in their 40s and 50s and affect their wellbeing. They can disturb sleep and concentration, while also affecting relationships and the ability to work."
"The non-hormonal treatment, called Veoza, is a daily pill which blocks nerve pathways in the brain that trigger the symptoms. Around 500,000 women could benefit from the drug, particularly those who cannot use HRT because of underlying health conditions, whose options up until now have been limited."
Veoza, also known as fezolinetant, is a non-hormonal treatment now available on the NHS in England for managing menopausal hot flushes and night sweats when hormone replacement therapy is not suitable. The drug works by blocking nerve pathways in the brain that trigger these symptoms. Menopausal symptoms significantly impact quality of life for women in their 40s and 50s, affecting sleep, concentration, relationships, and work ability. Approximately 500,000 women could benefit from this treatment, particularly those with underlying health conditions preventing HRT use. NICE approved the drug based on evidence showing it meaningfully reduces symptoms and offers cost-effectiveness for taxpayers, providing much-needed relief for women with limited treatment options.
Read at www.bbc.com
Unable to calculate read time
Collection
[
|
...
]